CMRX Chimerix Inc

Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that M. Michelle Berrey, M.D., M.P.H, President and Chief Executive Officer of Chimerix, will present at the Cowen and Company 38th Annual Health Care Conference on Wednesday, March 14, 2018 at 8:00 a.m. ET at the Boston Marriott Copley Place.

A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix’s website at ir.chimerix.com, where it will be archived for approximately 90 days.

About ChimerixChimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients.  Chimerix's proprietary lipid conjugate technology and compound library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and a new clinical candidate, CMX521, the first direct-acting antiviral specifically for the treatment and prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.

CONTACT:

Investor Relations:Michelle LaSpaluto(919) 972-7115 ir@chimerix.com or Will O’Connor Stern Investor Relations Will@sternir.com   212-362-1200

Media: Becky VonsiatskyW2O Groupbvonsiatsky@w2ogroup.com  413-478-2003